Comparison of Fixed-Dose, Dose-Escalated Hydroxyurea in Pediatric Sickle Cell Anemia
Investigators compared fixed dose and dose escalation administration of hydroxyurea in pediatric patients with sickle cell anemia.
Sickle Cell Disease
Graft, Survival Outcomes After Liver Transplant in Patients With Sickle Cell Disease
Investigators analyzed graft and survival outcomes among patients with SCD who received liver transplants.
How Do Sleep Disturbances in Sickle Cell Disease Affect Executive, Psychological Functioning?
For patients with SCD, anxiety significantly mediates the effect of sleep disturbances on executive functioning more than depression.
Baseline Patient-Reported Outcomes in Sickle Cell Disease
A report from the Sickle Cell Disease Implementation Consortium assessed patient-reported outcomes and clinical and psychosocial factors in SCD.
ASH 2020 Clinical Guidelines: Sickle Cell Disease and Cerebrovascular Disease
ASH published new clinical guidelines on the prevention, diagnosis, and treatment of CNS complications for children and adults with sickle cell disease.
Imatinib as Potential Tyrosine Kinase Inhibitor to Treat Sickle Cell Disease
Although SCD is often linked to microvasculature occlusion, some sequelae are caused by erythrocyte membrane weakening.
Patient-Centered Medical Home Model for Pediatric Sickle Cell Disease
Parents of infants and young children with sickle cell disease were satisfied with the patient-centered medical home model experience in the newborn cohort clinic setting.
F-Erythroblasts Not Significantly Different From Non-HbF-Expressing Cells
Neither transcriptional nor proteomic profiling revealed significant differences between F- and A-cells at baseline or after HbF-inducing treatment.
HIV Resistance in Patients With Sickle Cell Disease
Researchers found that individuals with sickle cell disease have lower HIV infection rates, slower progression to AIDS, and lower HIV-associated mortality.
Novel Pyruvate Kinase Activator Gets Orphan Drug Status for Sickle Cell Disease
The Food and Drug Administration (FDA) has granted Orphan Drug designation to FT-4202 (FORMA Therapeutics) for the treatment of sickle cell disease (SCD).
-
Loading...
-
Loading...
